1880 S Dairy Ashford Rd, Suite 650, Houston, TX 77077

Opioid Use Disorder Market Expected to Reach USD 6.15 Billion by 2030: SNS Insider


The global Opioid Use Disorder (OUD) market has witnessed significant growth in recent years, driven by various factors including increased awareness, improved treatment options, and rising incidences of opioid addiction. According to recent market analysis, The global opioid use disorder market size was valued at USD 3.13 billion in 2022 and is expected to reach USD 6.15 billion by 2030, registering a robust compound annual growth rate (CAGR) of 8.8% during the forecast period from 2023 to 2030, according to a new market research report.

Opioid Use Disorder Market
Opioid Use Disorder Market

Market Analysis:

The surge in opioid addiction cases globally has been a primary driver for the expansion of the OUD market. Factors such as over-prescription of opioids for pain management, the influx of illicit opioids, and the lack of access to effective treatment have contributed to the growing epidemic. Moreover, increased government initiatives and public awareness campaigns have fueled demand for OUD treatments.

The MOAT segment dominates the market, with drugs like buprenorphine, methadone, and naltrexone playing a pivotal role in managing opioid dependence. Behavioral therapies, including cognitive-behavioral therapy (CBT) and contingency management, complement pharmacological interventions, offering comprehensive treatment approaches.

Download Free Sample Report of Opioid Use Disorder (OUD) Market @ https://www.snsinsider.com/sample-request/3018

List of Opioid Use Disorder (OUD) Companies Profiled in Report:

  • Indivior PLC
  • Alkermes
  • Orexo AB
  • Titan Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Mallinckrodt Pharmaceuticals
  • BioDelivery Sciences International Inc.
  • Viatris Inc.
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC

Key Findings from the Report:

  • By Drug: The buprenorphine segment is expected to dominate the market, owing to its proven efficacy and safety profile in treating opioid addiction.
  • By Route of Administration: The oral route of administration is anticipated to capture the largest market share, driven by its convenience and patient preference.
  • By Distribution Channel: Hospital pharmacies are projected to lead the market, as many OUD treatments are initiated in healthcare settings under medical supervision.
  • By Region: North America is expected to hold the largest market share, primarily due to the high prevalence of opioid addiction and the availability of various treatment options in the region.

Regional Analysis:

  • North America (42% market share in 2022): Largest market due to the opioid epidemic, increasing investments in addiction treatment, and availability of advanced therapeutic options.
  • Europe (29%): Rising prevalence of opioid dependence, favorable reimbursement policies, and growing adoption of medication-assisted treatments are driving market growth.
  • Asia Pacific (18%): Emerging market with increasing awareness about opioid addiction and improving healthcare infrastructure.

Key Developments in the Opioid Use Disorder Market:

  • In 2022, the FDA approved Camurus’ long-acting buprenorphine injection, Brixadi, for the treatment of opioid use disorder.
  • Indivior and Opiant Pharmaceuticals collaborated in 2021 to develop a novel overdose reversal medication.
  • Launch of innovative digital therapeutics and telepsychiatry solutions for opioid addiction treatment by key players.

Key Takeaways from the Opioid Use Disorder Market Study:

  • Rising incidence of opioid addiction, coupled with the growing acceptance of medication-assisted treatments, is fueling market growth.
  • The buprenorphine segment dominated the market in 2022, driven by its proven efficacy and wide availability.
  • Increasing investments in research and development of novel opioid use disorder treatments are expected to create new growth opportunities.

Have Any Query? Ask Our Experts @ https://www.snsinsider.com/enquiry/3018

Emerging Trends and Opportunities:

Technological advancements, such as telemedicine and digital health platforms, are revolutionizing the delivery of OUD treatment and support services. These innovations facilitate remote monitoring, counseling sessions, and medication management, improving access to care and patient outcomes.

Furthermore, personalized medicine and genetic testing are emerging as promising avenues in the OUD market. Tailoring treatment plans based on individual genetic predispositions and metabolic profiles holds the potential to enhance treatment efficacy and minimize adverse effects.

Challenges and Considerations:

Despite the promising growth prospects, the OUD market faces several challenges. Stigma associated with addiction often impedes individuals from seeking help, highlighting the need for intensified awareness campaigns and community support initiatives. Additionally, regulatory hurdles and reimbursement policies pose challenges for market players, necessitating collaboration between healthcare providers, policymakers, and industry stakeholders to streamline processes and ensure equitable access to treatment.

Moreover, the opioid epidemic is a complex issue intertwined with socio-economic factors, necessitating a multifaceted approach that addresses underlying root causes such as poverty, trauma, and mental health disorders.

Data-driven Recommendations for Market Entry and Growth:

  • Investment in R&D: Continued investment in research and development is essential to innovate new therapies and enhance existing treatment modalities.
  • Expansion of Telehealth Services: Leveraging telemedicine platforms can broaden access to OUD treatment in underserved regions and facilitate ongoing care management.
  • Collaborative Partnerships: Forming strategic partnerships with healthcare providers, advocacy groups, and regulatory bodies can facilitate market entry and navigate regulatory complexities.
  • Education and Training: Investing in healthcare professional training programs and public education initiatives can mitigate stigma and promote early intervention.

Purchase Opioid Use Disorder (OUD) Market Report @ https://www.snsinsider.com/checkout/3018

About US:

SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.

We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.

Contact Us:

Akash Anand – Head of Business Development & Strategy,

info@snsinsider.com,

Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),

Website: https://www.snsinsider.com/